Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Roti Roti, Elon C ^a   Ringelstetter, Ashley K ^a   Kropp, Jenna ^a,c   Abbott, David H ^a,b   Salih, Sana M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DNA; DOXORUBICIN; HISTONE H2AX; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIRTH WEIGHT; CELL TYPE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG ACCUMULATION; FEMALE; FEMALE FERTILITY; FERTILITY PRESERVATION; INHIBITION KINETICS; LITTER SIZE; MOUSE; NONHUMAN; OVARY CELL; OVARY FOLLICLE; OVARY FOLLICLE ATRESIA; OVARY INSUFFICIENCY; OVARY PROTECTION; PROPHYLAXIS; PROTECTION; PROTEIN PHOSPHORYLATION; PUP (RODENT); ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FERTILITY; HUMAN; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PRIMARY OVARIAN INSUFFICIENCY;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIRTH WEIGHT; BORONIC ACIDS; BORTEZOMIB; DNA DAMAGE; DOXORUBICIN; FEMALE; FERTILITY; HUMANS; LITTER SIZE; MICE; OVARIAN FOLLICLE; OVARIAN NEOPLASMS; OVARY; PRIMARY OVARIAN INSUFFICIENCY; PYRAZINES;

EID: 84907459282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108174     Document Type: Article

References (44)

1. Hewitt M, Breen N, Devesa S (1999) Cancer prevalence and survivorship issues: Analyses of the 1992 National Health Interview Survey. Journal of the National Cancer Institute 91: 1480-1486.
2. Woodruff TK (2010) The Oncofertility Consortium-addressing fertility in young people with cancer. Nature Reviews Clinical Oncology 7: 466-475.
3. Oktay K, Oktem O (2009) Fertility Preservation Medicine: A New Field in the Care of Young Cancer Survivors. Pediatric Blood & Cancer 53: 267-273.
4. Oktay K, Oktem O, Reh A, Vahdat L (2006) Measuring the impact of chemotherapy on fertility in women with breast cancer. Journal Of Clinical Oncology 24: 4044-4046.
5. Amato P, Brzyski R, Benward J, Stein A, Steinbock B, et al. (2013) Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertility and Sterility 100: 1224-1231.
6. Adams J (2001) Proteasome inhibition in cancer: Development of PS-341. Seminars In Oncology 28: 613-619.
7. Zelinski MB, Murphy MK, Lawson MS, Jurisicova A, Pau KYF, et al. (2011) In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertility and Sterility 95: 1440-U1289.
8. Kim SY, Cordeiro MH, Serna VA, Ebbert K, Butler LM, et al. (2013) Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell Death and Differentiation 20: 987-997.
9. Roness H, Kalich-Philosoph L, Carmely A, Fishel-Bartal M, Ligumsky H, et al. (2013) Cyclophosphamide triggers follicle activation causing ovarian reserve 'burn out'; AS101 prevents follicle loss and preserves fertility. Human Reproduction 28: 46-47.
10. Roti Roti EC, Salih SM (2012) Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biology of Reproduction 86: 1-11.
11. Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, et al. (2014) Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Human Reproduction 29: 107-113.
12. Ting AY, Petroff BK (2010) Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. Journal of Assisted Reproduction and Genetics 27: 591-597.
13. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE (2008) Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Research and Treatment 110: 411-416.
14. Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nature reviews Urology 7: 245-257.
15. Smith MA, Freidlin B, Ries LA, Simon R (1998) Trends in reported incidence of primary malignant brain tumors in children in the United States. Journal of the National Cancer Institute 90: 1269-1277.
16. Society AC (2011) Cancer Facts and Figures 2011. http://wwwcancergov/cancertopics/factsheet/Sites-Types/childhood.
17. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochemical Pharmacology 57: 727-741.
18. Hasinoff BB, Schroeder PE, Patel D (2003) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Molecular Pharmacology 64: 670-678.
19. Swift LM, Sarvazyan N (2000) Localization of dichlorofluorescin in cardiac myocytes: implications for assessment of oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology 278: H982-H990.
20. Kujjo LL, Chang EA, Pereira RJG, Dhar S, Marrero-Rosado B, et al. (2011) Chemotherapy-Induced Late Transgenerational Effects in Mice. Plos One 6.
21. Kerr JB, Brogan L, Myers M, Hutt KJ, Mladenovska T, et al. (2012) The primordial follicle reserve is not renewed after chemical or gamma-irradiation mediated depletion. Reproduction 143: 469-476.
22. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, et al. (2010) Doxorubicin-induced ovarian toxicity. Reproductive Biology And Endocrinology 8.
23. Roti Roti EC, Leisman SK, Abbott DH, Salih SM (2012) Acute Doxorubicin Insult in the Mouse Ovary Is Cell- and Follicle-Type Dependent. Plos One 7.
24. Kiyomiya K, Matsuo S, Kurebe M (2001) Mechanism of specific nuclear transport of adriamycin: The mode of nuclear translocation of adriamycin-proteasome complex. Cancer Research 61: 2467-2471.
25. Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: Paradigm of a self-compartmentalizing protease. Cell 92: 367-380.
26. Nederlof PM, Wang HR, Baumeister W (1995) Nuclear localization signals of human and Thermoplasma proteasomal alpha subunits are functional in vitro. Proceedings of the National Academy of Sciences of the United States of America 92: 12060-12064.
27. Kiyomiya K, Matsuo S, Kurebe M (1998) Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sciences 62: 1853-1860.
28. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, et al. (2007) Topoisomerase II beta-Mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research 67: 8839-8846.
29. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Research 64: 4912-4918.
30. Huang HB, Liu NN, Yang CS, Liao SY, Guo HP, et al. (2012) HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert AntiTumor Activity In Vitro and In Vivo. Plos One 7.
31. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, et al. (1998) Inhibition of nuclear factor kappa B activation attenuates apoptosis resistance in lymphoid cells. Blood 91: 4624-4631.
32. Flaws JA, Abbud R, Mann RJ, Nilson JH, Hirshfield AN (1997) Chronically elevated luteinizing hormone depletes primordial follicles in the mouse ovary. Biology of Reproduction 57: 1233-1237.
33. Buss JL, Hasinoff BB (1993) The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents and Actions 40: 86-95.
34. Buss JL, Hasinoff BB (1995) Ferrous ion strongly promotes the ring-opening of hte hydrolysis intermediates of the antioxidant cardioprotective agent dexrazox-ane (ICRF-187). Archives of Biochemistry and Biophysics 317: 121-127.
35. Della Torre P, Imondi AR, Bernardi C, Podesta R, Moneta D, et al. (1999) Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Cancer Chemotherapy and Pharmacology 44: 138-142.
36. Della Torre P, Mazue G, Podesta A, Moneta D, Sammartini U, et al. (1999) Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane. Cancer Chemotherapy and Pharmacology 43: 151-156.
37. Hasinoff B (2002) Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovascular Toxicology 2: 111-118.
38. Hasinoff BB, Chee GL, Thampatty P, Allan WP, Yalowich JC (1999) The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anti-Cancer Drugs 10: 47-54.
39. Zheng WJ, Zhang H, Gorre N, Risal S, Shen Y, et al. (2014) Two classes of ovarian primordial follicles exhibit distinct developmental dynamics and physiological functions. Human Molecular Genetics 23: 920-928.
40. Eppig JJ, O'Brien M, Wigglesworth K (1996) Mammalian oocyte growth and development in vitro. Molecular reproduction and development 44: 260-273.
41. Pedersen T (1970) Determination of follicle growth rate in the ovary of the immature mouse. Journal of reproduction and fertility 21: 81-93.
42. Bristol-Gould SK, Kreeger PK, Selkirk CG, Kilen SM, Mayo KE, et al. (2006) Fate of the initial follicle pool: Empirical and mathematical evidence supporting its sufficiency for adult fertility. Developmental Biology 298: 149-154.
43. Green DM, Sklar CA, Boice JD, Mulvihill JJ, Whitton JA, et al. (2009) Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment: Results From the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 27: 2374-2381.
44. Bar J, Davidi O, Goshen Y, Hod M, Yaniv I, et al. (2003) Pregnancy outcome in women treated with doxorubicin for childhood cancer. American Journal of Obstetrics and Gynecology 189: 853-857.